Agenus Inc
NASDAQ:AGEN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Agenus Inc
Cash Interest Paid
Agenus Inc
Cash Interest Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Interest Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Agenus Inc
NASDAQ:AGEN
|
Cash Interest Paid
$1.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash Interest Paid
$3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
19%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash Interest Paid
$1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash Interest Paid
$12.4m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-18%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash Interest Paid
$41.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
15%
|
|
Agenus Inc
Glance View
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 441 full-time employees. The company went IPO on 2000-02-04. The company has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, vaccines and adjuvants. Its antibody candidates are Balstilimab (an anti-PD-1 antibody) and Zalifrelimab (an anti-CTLA-4 antibody), which is in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Its clinical-stage asset portfolio also includes Botensilimab (AGEN1181), AGEN2373, AGEN1423, AGEN1777, MK-4830, INCAGN2390, INCAGN2385 and AGENT 797. The company is developing personalized vaccines, namely Prophage and AutoSynVax, and off-the-shelf vaccines PhosphoSynVax, which contains heat shock proteins to deliver neoantigens to the right immune cells to activate an anti-cancer immune response.
See Also
What is Agenus Inc's Cash Interest Paid?
Cash Interest Paid
1.2m
USD
Based on the financial report for Dec 31, 2025, Agenus Inc's Cash Interest Paid amounts to 1.2m USD.
What is Agenus Inc's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 10Y
1%
Over the last year, the Cash Interest Paid growth was -48%. The average annual Cash Interest Paid growth rates for Agenus Inc have been 1% over the past three years , and 1% over the past ten years .
